Disposition and tolerance of suxibuzone in horses.

This study examined the effects of the drug Suxibuzone (SBZ), a non-steroidal anti-inflammatory drug, in horses. The research found that the drug was quickly metabolized and distributed in horses, and was well tolerated even when administered intravenously.

Introduction

In this research study, the scientists were focusing on the nonsteroidal anti-inflammatory drug Suxibuzone (SBZ). This drug was administered to six horses and then the scientists measured the levels of SBZ and its metabolites in the horses’ plasma and synovial fluid.

Methodology

• The researchers selected six horses and administered the drug Suxibuzone intravenously at a dose rate of 7.5 mg/kg of the horse’s body weight.
• They then utilized a specialized method known as high-performance liquid chromatography to measure the concentration of SBZ and its metabolites (phenylbutazone or PBZ, and oxyphenbutazone or OPBZ) in both plasma and synovial fluid samples from the horses.
• A noncompartmental analysis was used to determine the pharmacokinetic parameters or the movement of drugs within the body.

Results

• The researchers found that after the treatment, the plasma concentrations of SBZ rapidly decreased and were undetectable beyond 20 minutes.
• The main drug was not detected in any synovial fluid samples – only its metabolites PBZ and OPBZ were found.
• The average maximum plasma concentrations of PBZ and OPBZ were reached at 0.76 hour and 7.17 hours, respectively. This signifies how fast the SBZ was converted into its active forms inside the horse’s body.
• The mean residence time, which is the average time a drug stays in the body, was also calculated. PBZ had a mean residence time in plasma of approximately 6.96 hours while OPBZ was detectable for at least 24 hours with a mean residence time of about 10.65 hours.
• The researchers also observed that plasma concentrations of PBZ and OPBZ exceeded the levels necessary for anti-inflammatory effects (as indicated by EC50 and IC50) at least 12 hours after administering suxibuzone.
• Additionally, the synovial fluid concentrations of PBZ and OPBZ exceeded the levels necessary for PGE2 inhibition (another marker of anti-inflammatory action) at least 9 hours after administering suxibuzone.
• Finally, the horses showed no adverse effects or intolerance to the intravenous injection of suxibuzone.

Conclusion

This study concluded that suxibuzone was rapidly metabolized and well tolerated when administered intravenously in horses. This suggests that it could be a safe and effective anti-inflammatory medication for use in this species.